Revatio Labeling Includes Warning On “Visual Disturbances”

Labeling for Pfizer's Revatio (sildenafil) includes a warning on the possibility of "visual disturbances" at doses higher than 20 mg three times daily for the treatment of pulmonary arterial hypertension

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet